PARP and PI3K inhibition in pancreatic cancer: intravital insights and ‘fine-tune’ priming using AKT and single/double-strand DNA break biosensor mice.

实体瘤组织中的无效药物反应通常是癌症治疗临床有效性的限制因素。使用尖端的成像技术和模拟疾病的3D模型，我们可以在化疗的肿瘤不同区域内绘制药物反应不良的区域。在这里，我们将改变限制这些领域有效药物靶向的因素，以改善PI3K和DNA修复抑制剂在胰腺癌中令人鼓舞的抗癌作用。

Inefficient drug response in solid tumour tissue is often a limiting factor in the clinical effectiveness of cancer therapies. Using cutting-edge imaging technology and 3D models that mimic the disease, we can map areas of poor drug response within distinct regions of tumours with chemotherapy. Here, we will shift factors limiting efficient drug targeting in these areas to improve the encouraging anti-cancer profile of PI3K and DNA repair inhibitors in pancreatic cancer.